Clinical trials: Stage IB Breast Cancer
Advanced Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients
This Phase Ib/II study is an openlabel, multicenter study for patients with solid tumors and breast cancer amenable to anthracyclin therapy.
- Trial name
- NCT01131364
- Testing
- F16IL2 in combination with doxorubicin
- Where
- 5 sites in Italy
- Volunteers
- 29 people
- Sponsor
- Philogen S.p.A.
Breast Cancer
Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)
Primary objectives : 1. To evaluate the recommended dose of the combination of paclitaxel, gemcitabine, and lapatinib (Tykerb®) (PGT) as preoperative chemotherapy in patients with HER2 positive operable breast cancer Secondary…
- Trial name
- PGT (NCT01133912)
- Testing
- paclitaxel, gemcitabine, lapatinib
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Jungsil Ro
Neoplasms, Breast
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.
- Trial name
- NCT00790816
- Testing
- Lapatinib in combination with an anti-cancer agent, Lapatinib, Lapatinib in combination with an anti-cancer agent as specified by parent protocol
- Where
- 23 sites in United States, Canada and 3 more
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
This research study is studying a combination of drugs as a possible treatment for breast cancer with a BRCA mutation. The interventions involved in this study are: Sapacitabine (CYC682) Olaparib (Lynparza™)
- Trial name
- NCT03641755
- Testing
- Sapacitabine, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Head and Neck Cancer
Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema
RATIONALE: Acupuncture and moxibustion may improve well-being and quality of life in patients with lymphedema caused by breast cancer or head, neck, and throat cancer.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphedema
- Trial name
- AMWELL-SL (NCT00828516)
- Testing
- Acupuncture and moxibustion
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- East and North Hertfordshire NHS Trust
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination.
- Trial name
- CHARGE (NCT04315233)
- Testing
- Ribociclib, Belinostat
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Liver Metastases
CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer
This is an open label, fixed dose, phase Ib trial of anti-CEA CAR-T cell infusions delivered via the hepatic artery or splenic vein using the Surefire Infusion System (SIS) for patients with CEA-expressing liver metastases or…
- Trial name
- HITM-SURE (NCT02850536)
- Testing
- anti-CEA CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Roger Williams Medical Center
Metastatic Breast Cancer
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
The purpose of this research study is to look at the safety and side effects of combining the drug pembrolizumab with imiquimod, GM-CSF, and cryotherapy to treat breast cancer that includes skin lesions.
- Trial name
- NCT03982004
- Testing
- Epicutaneous cryoimmunotherapy, Topical imiquimod, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Triple Negative Breast Cancer, Breast Cancer
ImmunoBreast - A Phase Ib Study
A phase Ib study to investigate the safety, tolerability and trends of efficacy of ALECSAT treatment as an add-on therapy to carboplatin and gemcitabine in patients with locally advanced or metastatic triple-negative breast…
- Conditions
- Triple Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT04609215
- Testing
- ALECSAT
- Where
- 2 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Henrik Ditzel
Advanced/ Metastatic Her-2 Positive Breast Cancer
GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
The aim of this trial is to study the safety, pharmacokinetics and preliminary efficacy of the HER2-targeted antibody-drug conjugate GQ1001 in combination with pyrotinib in patients with HER2-positive metastatic breast cancer…
- Trial name
- NCT05575804
- Testing
- GQ1001+pyrotinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Sleep Disorder, Stage IA Breast Cancer
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
This randomized phase II trial studies how well brief behavioral therapy works in improving sleep disorders in patients with stage I-III breast cancer undergoing chemotherapy.
- Conditions
- Sleep Disorder, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT02002533
- Testing
- Brief Behavioral Therapy, Telephone-Based Intervention, Educational Intervention
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gary Morrow
Breast Cancer
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or…
- Trial name
- MoonROSE (NCT07100106)
- Testing
- GDC-4198, Giredestrant, Abemaciclib
- Where
- 77 sites in United States, Australia and 8 more
- Volunteers
- 285 people
- Sponsor
- Genentech, Inc.
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
This phase II trial studies how well carbon dioxide fractional (CO2RE) laser works in treating participants with stage 0-III hormone receptor-positive breast cancer with vulvovaginal atrophy associated with dryness, inflammation…
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT03666819
- Testing
- Carbon Dioxide Fractional Laser, Questionnaire Administration
- Sponsor
- Mayo Clinic
Breast Cancer
Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer
The overall rationale of this study evaluating tolerance and efficacy of LY2780301 in combination with paclitaxel in HER2-negative, inoperable locally advanced or metastatic breast cancer (MBC) is based on : the medical need in…
- Trial name
- TAKTIC (NCT01980277)
- Testing
- LY2780301 + paclitaxel
- Where
- 2 sites in France
- Volunteers
- 68 people
- Sponsor
- Institut Paoli-Calmettes
Cancer Survivor, Early-Stage Breast Carcinoma
Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)
This randomized phase III trial studies how well mindfulness meditation or survivorship education work in improving behavioral symptoms in younger stage 0-III breast cancer survivors.
- Conditions
- Cancer Survivor, Early-Stage Breast Carcinoma, Stage 0 Breast Cancer, Stage IA Breast Cancer
- Trial name
- PTW (NCT03025139)
- Testing
- Educational Intervention, Laboratory Biomarker Analysis, Meditation Therapy
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer, Tobacco Use Disorder
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
RATIONALE: Continued smoking after a cancer diagnosis has important health consequences beyond the risks associated with smoking in the general population.
- Conditions
- Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer
- Trial name
- NCT01434342
- Testing
- Nicotine Replacement Patch
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Wake Forest University Health Sciences
Advanced/Recurrent Breast Cancer, Endometrial Cancer
A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer
A study to examine the combination of temsirolimus and Caelyx® (chemotherapeutic) in advanced or recurrent breast, endometrial and ovarian cancer.
- Conditions
- Advanced/Recurrent Breast Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00982631
- Testing
- Temsirolimus/PLD
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Breast Cancer
CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer
This is a Phase 1 Trial. Crizotinib is a medication that is taken by mouth. It has shown that it can help slow down or stop the growth of tumor cells. The marketing name of the drug is "Xalkori".
- Trial name
- CRIZENT (NCT02074878)
- Testing
- Crixotinib 200 mg and Sunitinib Cohort 1, Crixotinib 250 mg and Sunitinib Cohort 2, Crizotinib & Sunitinib 37.5 mg Cohort 3
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mothaffar Rimawi
Advanced or Metastatic ER+ Breast Cancer
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with…
- Trial name
- NCT02734615
- Testing
- LSZ102, LEE011, BYL719
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Cancer Survivor, Stage 0 Breast Cancer
Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors
This clinical trial studies a cardiac rehabilitation program in improving cardiorespiratory fitness in stage 0-III breast cancer survivors.
- Conditions
- Cancer Survivor, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT03039140
- Testing
- Educational Intervention, Exercise Intervention, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center